As part of the new quinquennium, Cardiff ECMC has begun setting up an ECMC Haematology network.
The main purpose of the network is to promote haematology activities within the ECMC, and consider ways in which a collective group can:
· Attract more early-phase haematology trials within the ECMC and share information about them
· Initiate academic early-phase trials (ideas and proposals, joining up infrastructure etc)
The ECMC Translational Science subgroup of QATS (Quality Assurance & Translational Science group) organised its very first conference titled ‘Opportunities and challenges with emerging biomarker technologies and their application in early phase trials’ on 20 March. The one-day event was held at the ICR in Sutton and organised by Karen Swales, Senior Scientific Officer, ICR CRUK Therapeutics Unit and chair of the Translational Science subgroup.
Both the CRUK Stratified Medicine Programme (SMP2) and the National Lung Matrix Trial (NLMT) are at a crucial phase of trial delivery.
SMP2 and NLMT are open to recruitment at 17 and 16 ECMCs respectively. Both study teams are collaborating to set up three new sites (Liverpool, Maidstone and Devon and Exeter) as part of a phased approach that aims to introduce several new sites across the country.
The development of new treatments for pancreatic cancer is set to be transformed by a £10m investment by Cancer Research UK into a network of clinical trials, aiming to find the right trial for the right patient.
The UK’s only current trial dedicated to the treatment of myelomonocytic leukaemia (CMML) has recruited its first patient. The Phase II MONOCLE study has opened at the Institute of Cancer & Genetics at Cardiff University, and has received funding support from the Cardiff ECMC.
A Phase I-II study supported by UCL ECMC has found that rucaparib can be used in the treatment of patients with high-grade ovarian cancer.
This study was the first to fully evaluate single-agent oral rucaparib, a PARP inhibitor, in patients with advanced solid tumors who had already undergone significant treatment for their cancer.
Welsh patients are to be some of the first in the world to access the drug-radiation combination trial, known as PARADIGM 2. The trial is co-funded by Cancer Research UK and The Brain Tumour Charity, and is part of CRUK’s ECMC Combinations Alliance and will be run at Velindre Cancer Centre by Dr James Powell.
From Monday 10 April, Dr Ilaria Mirabile of the ECMC Programme Office is taking on a new role as Network Lead.
As we enter the new five year funding period, Ilaria says that she is thrilled to be taking on the promotion, and is excited about the opportunities that lie ahead for the Network as a whole.